Key Highlights

  • Loss per share was USD 9.59 against an estimate of a USD 13.00 loss.
  • Net loss was USD 6.49 million, compared with USD 25.40 million.
  • Research and development expenses were USD 4.49 million, compared with USD 3.74 million.
  • Cash was USD 7.29 million at September 30, 2026.

Moleculin Biotech (NASDAQ:MBRX) reported a net loss of USD 6.49 million for the third quarter of 2026, compared with USD 25.40 million in the prior-year quarter. Net loss per common share was USD 9.59, compared with USD 340.43, against an estimate of a USD 13.00 loss.

Net loss available to common stockholders was USD 7.27 million, after Warrant deemed dividends of USD 773 thousand. The company reported no Revenue for the periods presented.

Operating Expenses

Research and development expenses were USD 4.49 million, compared with USD 3.74 million, and general and administrative expenses were USD 2.11 million, compared with USD 2.15 million. Total operating expenses were USD 6.61 million, compared with USD 5.91 million, and the loss from operations was USD 6.61 million, compared with USD 5.91 million.

The gain from the change in Fair Value of the warrant Liability was USD 35 thousand, compared with USD 1.59 million. Weighted average common shares outstanding were 757,858, compared with 74,609.

Nine-Month Results

For the nine months ended September 30, 2026, Research and Development expenses were USD 15.32 million, compared with USD 10.77 million, and total operating expenses were USD 22.05 million, compared with USD 17.57 million. The gain from the change in fair value of the warrant liability was USD 10.80 million, compared with USD 1.03 million.

The net loss for the nine months was USD 26.97 million, compared with USD 49.11 million, and net loss per common share was USD 71.38, compared with USD 1,179.03. Warrant deemed dividends were USD 2.87 million.

Cash, Liquidity and Clinical Program

Cash and cash equivalents were USD 7.29 million at September 30, 2026, compared with USD 8.88 million at the prior Balance Sheet date. Intangible Assets were USD 11.15 million. The filing states that management anticipates cash on hand is not sufficient to fund planned operations for a period of at least one year from when the financial statements are issued, and that these factors raise substantial doubt regarding the company's ability to continue as a going concern.

The filing states that Moleculin Biotech is conducting a pivotal Phase 2/3 trial evaluating Annamycin, also known as naxtarubicin, in combination with cytarabine for the treatment of subjects with relapsed or refractory acute myeloid leukemia. The registrant had 1,061,533 shares of common stock outstanding at November 6, 2026.

Total current assets were USD 8.41 million, compared with USD 9.69 million. Depreciation and amortization was USD 8 thousand, compared with USD 21 thousand, and net interest income was USD 58 thousand, compared with USD 39 thousand. The filing states that approximately 1.8 million and 0.2 million potentially dilutive shares were excluded from the computation of Diluted Earnings per Share due to their anti-dilutive effect.

Moleculin Biotech Q3 2026 Earnings: Key Takeaways

Moleculin Biotech reported a third quarter 2026 net loss of USD 6.49 million and a loss per share of USD 9.59. Cash and cash equivalents were USD 7.29 million at September 30, 2026.